Search clinical trials for: deferiprone extended release formulation

Total 7906 results

ApoPharma

Completed

Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers

Healthy

Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Recruiting

Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder

Schizophrenia, Schizoaffective Disorder

United States
Royal Victoria Hospital, Canada

Not yet recruiting

Monthly Versus Daily Buprenorphine Formulations for Treatment of Opiate Use Disorder (STOPIT)

Moderate to Severe Opioid Use Disorder

Canada
Bellus Health Inc. - a GSK company

Recruiting

Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation

Healthy | Cough

United Kingdom
University of British Columbia
Paladin Labs Inc.

Recruiting

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations (LCP-TAC)

Liver Transplantation | Neurotoxicity | Tremor | Tacrolimus | Immunosuppression

Canada
Monash Medical Centre
Monash University

Recruiting

FASST - Fetal Alcohol Spectrum Stimulant Trial (FASST)

Fetal Alcohol Spectrum Disorders

Australia
Rennes University Hospital

Recruiting

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release (DIPLOID)

Pharmacokinetics

France
Hangzhou Highlightll Pharmaceutical Co., Ltd

Completed

Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects

Atopic Dermatitis

China
Hillier, Sharon, PhD
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety and Pharmacokinetics of Two Vaginal Film Formulations Containing the Integrase Inhibitor MK-2048 (FAME103)

Pharmacokinetics | Safety

United States
Katherine Bunge
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Randomized Cross-Over Study of Self-Insertion of Two Placebo Vaginal Film Formulations (FAME103B)

Safety | Acceptability

United States
Otsuka Pharmaceutical Development & Commercialization...

Terminated

A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects

Adult Attention-deficit Hyperactivity Disorder (ADHD)

Australia
Ironshore Pharmaceuticals and Development, Inc

Completed

A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD (HLD100-103)

Attention-Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

Belgium
Shire

Completed

Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476

Colitis, Ulcerative

Belgium
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Evaluate Pharmacokinetics Of Two Different Pharmaceutical Oral Formulations Of Alprazolam And A Clonazepam Tablet In Mexican Healthy Population

Pharmacokinetics

Mexico
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers

Healthy

United States
UCB Pharma

Completed

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

Epilepsy

Brazil, Finland, India, Mexico, Russian Federation, South Africa, Ukraine
Food and Drug Administration (FDA)
Algorithme Pharma Inc; Vince & Associates Clinical Research, Inc.

Completed

A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects

Healthy

United States
Tocagen Inc.

Withdrawn

A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)

Bladder Cancer
University Health Network, Toronto
Canadian Society of Hospital Pharmacists

Withdrawn

Dosing Intervals of Opioid Medication for Chronic Pain

Chronic Pain

Canada
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Duke University

Completed

Effect of Bupropion on Seizure Threshold in Depressed Patients

MDD

United States
MediciNova

Completed

Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers

Healthy Volunteers

United States
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules in Healthy Adults

Healthy | Gastric Retention

Australia
Pfizer

Completed

Healthy Volunteers Study to Estimate the Effects of Food on the Bioavailability of Oxycodone and Naltrexone/6- Β -Naltrexol From a Extended Release Formulation of Oxycodone With Sequestered Naltrexone

Healthy

United States
GlaxoSmithKline

Withdrawn

Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects

Epilepsy, Partial

Japan
Bundang CHA Hospital

Completed

Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea

Peripheral Artery Disease

Korea, Republic of
Massachusetts General Hospital

Completed

Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD

Autism Spectrum Disorder | Attention-deficit/Hyperactivity Disorder

United States
Laboratorio Elea Phoenix S.A.
DominguezLab S.R.L.

Completed

Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.

Healthy

Argentina
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
GlaxoSmithKline

Terminated

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers

Diabetes Mellitus, Type 2

Australia
Yale University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

Alcohol Pharmacotherapy for HIV+ Prisoners (INSPIRE)

Alcohol Dependence | Human Immunodeficiency Virus | AIDS | Hazardous Drinking | Problem Drinking

United States
Alcobra Ltd.

Completed

Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects

Attention Deficit Hyperactivity Disorder

Israel
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers

Healthy | Pharmacokinetics of Quetiapine

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
GlaxoSmithKline

Completed

Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

Alzheimer's Disease

Germany
GlaxoSmithKline

Completed

RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole

Restless Legs Syndrome | Restless Legs Syndrome (RLS)

Spain, United States, Belgium, Sweden, Australia, Netherlands, United Kingdom, Italy, Austria, Germany, Denmark, France, Norway
GlaxoSmithKline

Completed

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

Epilepsy

United States
ApoPharma

Completed

Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers

Healthy

Canada
ApoPharma
Algorithme Pharma Inc

Completed

Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers

Healthy

Canada
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Healthy Volunteers | Pharmacokinetics of ASP015K | Food Effect

United States
Bayer

Completed

Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)

Seasonal Allergic Rhinitis | Vasomotor Rhinitis
Pfizer

Completed

Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers

Healthy

Belgium
GlaxoSmithKline

Completed

A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

Analgesia

United States
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy

3

Subscribe